Format

Send to

Choose Destination
PLoS One. 2016 Aug 4;11(8):e0158545. doi: 10.1371/journal.pone.0158545. eCollection 2016.

Co-Administration of Soy Isoflavones and Vitamin D in Management of Irritable Bowel Disease.

Author information

1
Department of Biology, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
2
National Nutrition and Food Technology Research Institute, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3
Digestive disease research center (DDRC), Digestive Disease Research Institute, Tehran, Iran.
4
Liver and pancreatic biliary research group, Digestive Disease Research Institute, Tehran, Iran.
5
Students' Research Committee, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
6
Students' Research Committee, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
7
Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.

Abstract

BACKGROUND AND AIMS:

The substantial characteristics of Irritable Bowel Syndrome (IBS) are associated with estrogens in women. Both soy isoflavones and vitamin D can modulate estrogen receptors in the colonic smooth muscles. The aim of this study was to investigate the effects of soy isoflavones, vitamin D and their probable interactions in women with IBS.

METHODS:

In a factorial blinded randomized clinical trial, 100 women with IBS (age:18-75yr, were randomly assigned in 4 arms to receive either placebo of vitamin D and placebo of soy isoflavones (P+P), or placebo of vitamin D and soy isoflavones (P+S), or vitamin D and placebo of soy isoflavones (D+P), or vitamin D and soy isoflavones (D+S) for 6 weeks. Dosage of soy isoflavone was 2 capsules of 20 mg soy isoflavones per day, and dosage of vitamin D was one pearl of 50'000 IU biweekly. The clinical outcomes were IBS symptoms severity scores (IBS-SSS), disease- specific quality of life (IBS-QOL) and total score (IBS-TS) that evaluated at weeks 0, 6, and 10, and compared to each other.

RESULTS:

IBS-TS improved significantly in both S+P and D+P groups (p- value = 0.004, 0.015). The interaction effect of soy isoflavones and vitamin D on IBS-TS was significant (p<0.05). The interaction effect of soy isoflavones with vitamin D and the main effect of vitamin D on IBS-SSS were not statistically significant, whereas IBS-SSS decreased significantly in S+P and D+P groups (p-value = 0.001, 0.047 respectively).

CONCLUSION:

Our results indicate that co-administration of soy isoflavones with vitamin D did not improve the IBS- SSS and IBS- QOL; however, it improved the IBS-TS.

TRIAL REGISTRATION:

Clinical Trials.gov NCT02026518.

PMID:
27490103
PMCID:
PMC4973900
DOI:
10.1371/journal.pone.0158545
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center